eIF2Bδ Inhibitors are a class of chemical compounds that specifically target the δ subunit of eukaryotic initiation factor 2B (eIF2B), a critical regulator in the process of protein synthesis. eIF2B is a guanine nucleotide exchange factor (GEF) that plays a pivotal role in the initiation of translation by catalyzing the exchange of GDP for GTP on eIF2, a process essential for the formation of the translation initiation complex. The eIF2B complex is composed of five subunits (α, β, γ, δ, and ε), with each subunit contributing to the overall function and regulation of the complex. The δ subunit, in particular, is crucial for the structural stability and proper assembly of the eIF2B complex, as well as for the interaction with eIF2.
Inhibitors that target eIF2Bδ disrupt the normal function of eIF2B, leading to a decrease in its GEF activity. This disruption impacts the global regulation of protein synthesis within the cell, as the reduced activity of eIF2B results in decreased levels of active eIF2-GTP, ultimately leading to a slowdown in translation initiation. By inhibiting eIF2Bδ, researchers can investigate the broader regulatory mechanisms of protein synthesis and how cells respond to various stress conditions that affect translation. These inhibitors are valuable tools for studying the cellular responses to changes in translation rates, the role of eIF2B in maintaining proteostasis, and the intricate signaling pathways that regulate protein synthesis in response to environmental cues. Furthermore, eIF2Bδ inhibitors provide insights into the complex interplay between different subunits of the eIF2B complex and their individual contributions to the regulation of translation, making them an essential resource in the field of molecular biology and biochemistry.
Items 11 to 18 of 18 total
画面:
製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
ドキソルビシンによるDNA損傷は、細胞が通常の機能よりもDNA修復を優先させる原因となり、RNAi機構を抑制し、eIF2C2レベルを低下させる可能性がある。 | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
カンプトテシンのトポイソメラーゼI阻害作用はDNA損傷を引き起こす可能性があり、その結果、RNAiプロセスへの集中が低下し、eIF2C2の発現が低下する可能性がある。 | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
ゲルダナマイシンはHsp90を阻害することで、RNAiに関連するタンパク質の安定性を低下させる可能性があり、eIF2C2の安定性や合成の低下が含まれる可能性がある。 | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
TAK-243は、ユビキチン活性化酵素(UAE)の低分子阻害剤であり、タンパク質の翻訳を阻害することで間接的にEIF3εに影響を与える。抗がん剤としての可能性について研究されている。 | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
EIF4AIの強力な阻害剤として知られる植物Aglaia foveolataから単離された天然化合物。 | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
EIF4AI に対する強い阻害活性を持つ、アグライア属などのいくつかの植物から発見された別の天然化合物。 | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
eIF4F 複合体を破壊し、キャップ依存性翻訳を阻害するように設計された合成 EIF4AI 阻害剤。 | ||||||
eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 | 315706-13-9 | sc-202597 | 10 mg | $260.00 | 14 | |
eIF4E-eIF4G の相互作用を破壊し、翻訳開始を阻害する低分子。 |